Neurology

Pediatric Neurology Organizations Partner, Receive Funding to Build Registry for Neonatal Hypoxic Ischemic EncephalopathyPediatric Neurology Organizations Partner, Receive Funding to Build Registry for Neonatal Hypoxic Ischemic Encephalopathy

Pediatric Neurology Organizations Partner, Receive Funding to Build Registry for Neonatal Hypoxic Ischemic Encephalopathy

WEST BLOOMFIELD TOWNSHIP, MI / ACCESSWIRE / October 31, 2024 / Cerebral Palsy Research Network, Hope for HIE and Newborn…

6 months ago
Bausch Health Announces Third Quarter 2024 ResultsBausch Health Announces Third Quarter 2024 Results

Bausch Health Announces Third Quarter 2024 Results

Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up…

6 months ago
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial…

6 months ago
How a 5-Year-Old is Helping Save Lives: New Book by Telestroke CEO & Son Teaches Kids to Spot Stroke SignsHow a 5-Year-Old is Helping Save Lives: New Book by Telestroke CEO & Son Teaches Kids to Spot Stroke Signs

How a 5-Year-Old is Helping Save Lives: New Book by Telestroke CEO & Son Teaches Kids to Spot Stroke Signs

EAST BRUNSWICK, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- On World Stroke Day, Dr. Rajiv Narula, founder and CEO of…

6 months ago
Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant SolutionGrifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes,…

6 months ago
Biogen Appoints Daniel Quirk, MD, as Chief Medical OfficerBiogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as…

6 months ago
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, TexasPlus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and…

6 months ago
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

6 months ago
JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging TechnologiesJACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies

JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies

– Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and…

6 months ago
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) RecurrenceACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 /…

6 months ago